Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
Inozyme Pharma (Nasdaq: INZY) announced that its CEO, Axel Bolte, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 29 at 1:20 p.m. ET. The presentation will focus on the company's development of novel therapeutics for rare diseases related to abnormal mineralization, particularly those caused by mutations in the ENPP1 and ABCC6 genes. Investors can access the live webcast from Inozyme's website, with an archived replay available for 60 days after the event.
- None.
- None.
BOSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, at 1:20 p.m. ET.
The presentation will be webcast live and can be accessed from the Investors & News section of Inozyme’s website under Events. An archived replay of the webcast will be available for up to 60 days following the event.
About Inozyme Pharma
Inozyme Pharma, Inc. (Nasdaq: INZY), is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.
Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.
Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of Investor Relations
stefan.riley@inozyme.com
Media:
SmithSolve
Alex Van Rees
(973) 442-1555 ext. 111
alex.vanrees@smithsolve.com
FAQ
When will Inozyme Pharma present at the 2021 Cantor Virtual Global Healthcare Conference?
Who is presenting for Inozyme Pharma at the Cantor Healthcare Conference?
What is the focus of Inozyme Pharma's presentation?
How can investors access Inozyme Pharma's presentation?
Will there be a replay of Inozyme Pharma's presentation available?
